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Abstract We have previously described an action-potential
and Ca
2+-dependent form of adenosine release in the
molecular layer of cerebellar slices. The most likely source
of the adenosine is the parallel fibres, the axons of granule
cells. Using microelectrode biosensors, we have therefore
investigated whether cultured granule cells (from postnatal
day 7–8 rats) can release adenosine. Although no purine
release could be detected in response to focal electrical
stimulation, purine (adenosine, inosine or hypoxanthine)
release occurred in response to an increase in extracellular
K
+ concentration from 3 to 25 mM coupled with addition of
1 mM glutamate. The mechanism of purine release was
transport from the cytoplasm via an ENT transporter.
This process did not require action-potential firing but
was Ca
2+dependent. The major purine released was not
adenosine, but was either inosine or hypoxanthine. In
order for inosine/hypoxanthine release to occur, cultures
had to contain both granule cells and glial cells; neither
cellular component was sufficient alone. Using the same
stimulus in cerebellar slices (postnatal day 7–25), it was
possible to release purines. The release however was not
blocked by ENT blockers and there was a shift in the Ca
2+
dependence during development. This data from cultures
and slices further illustrates the complexities of purine
release, which is dependent on cellular composition and
developmental stage.
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Introduction
The neuromodulator adenosine is involved in many
physiological and pathological CNS processes [1–3].
Although the actions of adenosine are reasonably well
characterised [4, 5] the mechanisms of extracellular
adenosine production are complex [3, 6, 7]. A large number
of studies, over many years have shown that adenosine can
be released from brain tissue by a number of different
stimuli (including hypoxia, ischemia, depolarisation, elec-
trical stimulation, etc.) and by a variety of mechanisms (for
review, see [7]). For example, an increase in extracellular
adenosine release could occur following extracellular ATP
metabolism (ATP can be released by exocytosis [7–9]o r
through gap junction hemi-channels [10]). Adenosine can
also be transported from the cell cytoplasm by equilibrative
transporters [7, 11, 12]. Recent data has described the
release of adenosine [13] which has the properties of
exocytosis (Ca
2+ and action-potential dependence) but there
is currently no direct evidence for either adenosine exocy-
tosis or vesicular storage. Once released, adenosine is
removed by conversion to inosine (by adenosine deaminase)
and taken up into neurones and glia by transporters
(equilibrative or concentrative).
We have previously shown that focal electrical stimulation
within the molecular layer of cerebellar slices can release
adenosine [13]. This process is both Ca
2+- and action-
potential-dependent, and several lines of evidence suggest
that parallel fibre (granule cell axons) activity is required for
adenosine release [13]. To show definitively that adenosine
is released from parallel fibres in cerebellar slices is difficult,
as parallel fibres could activate a downstream target which
then releases adenosine. Thus, we have taken the approach
of investigating whether isolated granule cells (in culture)
can release adenosine with a similar mechanism to that
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DOI 10.1007/s11302-010-9185-8observed in slices. We have used microelectrode biosensors,
which respond in real-time to changes in purine concentra-
tion [14, 15]. This is the first time that such biosensors have
been used with primary cultured cells.
Methods
Preparation of granule cell cultures
The method for preparing granule cell cultures is based
on [16].
Solution composition (quantities for one preparation)
Solution 1 (for 100 ml) NaCl 124 mM, KCl 5.4 mM,
NaH2PO4 1 mM, glucose 14.4 mM, phenol red 28 μM,
HEPES 20 mM, MgSO4 150 μM and 0.3 g bovine serum
albumin. The solution is filtered (sterile 0.2 μm filter) and
stored at 4°C.
Solution 2 Ten millilitres of solution 1, DNaseI 0.1 mg/ml,
trypsin inhibitor from soy bean 0.52 mg/ml (Invitrogen)
and 3.2 mM MgSO4.
Solution 3 Ten millilitres of solution 1, 130 μΜ CaCl2 and
2.6 mM MgSO4.
Neurobasal medium Twenty millilitres of Neurobasal
(Fisher), glutamine 1.5 mM, penicillin 10 U/ml streptomycin
10 μg/ml and 400 μl B-27 (50×, Fisher).
The cerebellum was removed from a postnatal day 7–
8 (P7–8) Wistar rat and transferred into Krebs solution
(NaCl 124 mM, KCl 5.4 mM, NaH2PO4 1 mM, glucose
14.4 mM, phenol red 28 μM, HEPES 20 mM, MgSO4
150 μM and bovine serum albumin 3 mg/ml). Meninges
and blood vessels were removed and following trituration
and centrifugation (302 G, 3 min), cells were incubated for
15minat37°CinKrebssolutioncontainingtrypsin(0.025%).
After centrifugation(302G,3min), cells wereresuspended in
Krebs solution, containing trypsin inhibitor (0.52 mg/ml) and
DNAse(0.1mg/ml),andpassedthrougha40-μmcellstrainer .
The suspension was spun at 484 G for 5 min and cerebellar
granule neurons were purified by a pre-plating step in
Neurobasal medium (1 h, 37°C). For the harvesting of glia,
coverslips were placed on the bottom of the dish so that the
glia could stick to them. The suspended neuronal cells were
plated on poly-l-ornithine coated coverslips (6–12 coverslips)
at an approximate density of 400,000 cells per coverslip.
Neurons were cultured in Neurobasal medium, containing
25 mM KCl, 2% B27, 1.5 mM glutamine, penicillin 10 U/ml
streptomycin and 10 μg/ml. For experiments in which the
proliferation of glial was reduced, the mitotic inhibitor (1 μM
β-D-arabinofuranoside hydrochloride) was added to the
Neurobasal media 24 h after culture preparation. The mitotic
inhibitor was then present in all media.
Immunohistochemistry
Following recording, coverslips were incubated in 4% para-
formaldehyde (in 0.1 M phosphate buffered saline, PBS) for
45minatroomtemperature.Thecoverslipswerethenblocked
in 10% horse serum 90% immunosolution (0.1 M PBS, 0.1%
BSA, 0.1% sodium azide, 0.4% triton X-100 and pH 7.4) for
1 h at room temperature. Coverslips were washed three times
(5-min washes) in 0.1 M PBS. The coverslips were incubated
with primary antibody to MAP2 (Mouse, Sigma, M4403) and
GFAP (Chick, Millipore, AB5541) at 1 in 500 for 2 h at room
temperature. Coverslips were washed three times (5-min
washes) in 0.1 M PBS. The coverslips were incubated with
the secondary antibody (one in 500) for 1 h at room
temperature. The secondary for GFAP was goat anti-chick
594 (Fisher) and for MAP2 was goat anti-mouse 488 (Fisher).
Preparation of cerebellar slices
Transverseslicesofcerebellarvermis(400µm)wereprepared
from male Wistar rats, at postnatal days 7–25 (P7–25). As
described previously [13] and in accordance with the U.K.
Animals (Scientific Procedures) Act (1986), male rats were
killed by cervical dislocation and decapitated. The cerebel-
lum was rapidly removed and slices were cut on a Microm
HM 650 V microslicer in cold (2–4°C) high Mg
2+,l o wC a
2+
aCSF, composed of (mM): 127 NaCl, 1.9 KCl, 8 MgCl2,0 . 5
CaCl2,1 . 2K H 2PO4,2 6N a H C O 3,1 0D-glucose (pH 7.4
when bubbled with 95% O2 and 5% CO2,3 0 0m O S M ) .
Slices were stored in normal aCSF (1.3 mM MgCl2,2 . 4m M
CaCl2) at room temperature for 1–6 h before recording.
Recording from granule cell cultures and cerebellar slices
An individual granule cell culture (on a coverslip) or a
cerebellar slice was transferred to a recording chamber,
submerged in aCSF and perfused at 6 ml/min (30–32°C).
The coverslip/slice was placed upon a suspended grid. All
solutions were vigorously bubbled (95% O2/5% CO2) and
all tubing had low gas permeability (Tygon). Purine bio-
sensors were positioned just above the surface of the
culture/slice (bent so their longitudinal surface was parallel
to the culture surface or parallel to the molecular layer of
cerebellar slices). Cultures were electrically stimulated with
a concentric bipolar electrode (FHC) placed on the coverslip
amongst the cells. Cultures were washed with aCSF for 20–
30 minutes (to remove culture medium) before recordings
were made.
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Biosensors were obtained from Sarissa Biomedical Ltd
(Coventry UK). Biosensors consisted of enzymes entrapped
within a matrix that was deposited around a Pt or Pt/Ir (90/10)
wire etched to ∼50 μM[ 14, 15]. The biosensors had an
exposed length of ∼500 μm that was coated with enzymes
and thus capable of detecting purines. Biosensors were
screened, which greatly reduced the responses to electro-
active interferents (such as 5-HT, noradrenaline, dopamine
and ascorbate). Four types of purine biosensor were used in
thisstudy.Firstly,ascreenednullsensor,possessingthematrix
but no enzymes, was used to control for the release of any
non-specific electro-active interferents. Secondly, screened
biosensors containing adenosine deaminase, nucleoside
phosphorylase and xanthine oxidase and (responsive to
adenosine, inosine and hypoxanthine, ADO biosensor).
Thirdly, screened biosensors containing nucleoside phos-
phorylase and xanthine oxidase (responsive to inosine,
hypoxanthine, INO biosensor). And finally, screened ATP
biosensors which consisted of the entrapped enzymes
glycerol kinase and glycerol-3-phosphate oxidase [15].
Glycerol (2 mM) was included in the aCSF, as glycerol is a
co-substrate required for ATP detection. A full description of
the properties of the biosensors has already been published
but they show a linear response to increasing concentration
of analyte, are fast to respond and have a rise time less than
10 s [14, 15]. Biosensors were calibrated with known
concentrations (10 μM) of adenosine, inosine and ATP.
Adenosine biosensors had approximately equal sensitivity to
adenosine, inosine and hypoxanthine. For non-differential
ADO biosensor recordings, the concentration of purines was
assessed from the adenosine or inosine calibration and is
equivalent to µmol/L′ [17]. The screening of sensors was
assessed by applying 10 μM of 5-HT. Calibration was
performed before theculture/slicewas presentinthe perfusion
chamber and after the culture/slice had been removed. This
allowed measurement of any reduction in sensitivity during
theexperiment.Biosensor signalswere acquiredat1kHz with
a Micro CED (Mark 2) interface using Spike (Vs 6.1)
software.
Drugs
All drugs were made up as 10–100 mM stock solutions,
stored frozen and then thawed and diluted with aCSF on the
day of use. Adenosine, inosine, NBTI, and dipyridamole
were purchased from Sigma. Erythro-9-(2-hydroxy-3-
nonyl) adenosine (EHNA) was purchased from Tocris–
Cookson. TTX was purchased from Ascent Scientific.
ATP was purchased from Roche. The mitotic inhibitor β-
D-arabinofuranoside hydrochloride was purchased from
Sigma.
All values are mean ± SEM. Statistical significance
(P<0.05) was assessed using the Student t test.
Results
Stimulation of granule cell cultures causes purine release
We have identified an action-potential and Ca
2+-dependent
form of adenosine release in the cerebellum [13]. One of
the most likely sources of the adenosine is parallel fibres
(granule cell axons). Thus, we have investigated whether
isolated granule cells (in culture) can release adenosine with
a similar stimulus. Initially, granule cells were cultured with
and without high (25 mM) K
+ concentrations in the media.
Granule cells without the high K
+ concentration died after a
few days and thus all experiments were conducted with
cells cultured in a high K
+ concentration (which lasted up
to ∼4 weeks).
Biosensors were placed upon the surface of individual
granule cell cultures (on glass coverslips). Using cultures
that were 2–3 weeks old, we were unable to detect purine
release following electrical stimulation, even with pro-
longed high-frequency trains (no difference between ADO
and null sensors, n=10 coverslips, data not shown). This is
not surprising as the stimulating electrode delivers a focal
electrical stimulus, which will only activate a small number
of cells directly under the stimulating electrode. In the slice,
granule cell axons are aligned in tracts (within the
molecular layer) and thus a large number will be activated
by a focal stimulus. Thus, a stimulus was used which will
depolarise all the cells in the culture, i.e. bath application of
excitants. Depolarisation of the cells with 10–50 mM KCl
did not produce reliable purine release (the ADO biosensor
response was the same as the null sensor, n=10 coverslips,
data not shown). Application of 100 μM–1 mM glutamate
also did not reliably release purines (n=12 coverslips, in
most coverslips (ten out of 12) there was no purine release,
in two cultures a small amount of purine release was
detected). However, the simultaneous application of 25 mM
KCl and 1 mM glutamate, reliably (14 out of 16 coverslips)
induced a large current (270±53 pA, range 49–813 pA) on
the ADO biosensor with little or no current on the null
sensor (Fig. 1a). The stimulus (25 mM KCl+1 mM
glutamate) had no direct effect on the ADO biosensor, as
once the biosensor was moved up from the culture surface
the stimulus no longer produced a current (n=3, Fig. 1b).
Thus, the current is produced by detection of released
purines and is equivalent to 1.8±0.2 μM′ of purines (see
“Methods” section).
The current produced by purine release had a slow time
to peak (100–150 s) and a slow decay (500–600 s, Fig. 1a).
As calibration curves for the sensors had a much faster rise
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illustrates the kinetics of release from the cultures which is
slow and prolonged (Fig. 1a, inset). Although most cultures
(88 %) responded to a single stimulus, subsequent stimuli
often produced a much smaller release of purines (45±15%
reduction, n=12 coverslips) suggesting a depletion of
internal purine stores. However, this was not always the
case, with some cultures releasing similar amounts of
purines with two to four stimuli (n=4 coverslips). With a
reduced stimulus, 10 mM KCl+100 μM glutamate or
100 μM–1 mM glutamate alone, it was sometimes possible
to release smaller amounts of purines (0.5±0.7 μM′, n=6
coverslips) which was sustainable for repeated stimuli (four
to five, not illustrated). However, purine release (with this
weaker stimulus) was not reliable, with many cultures (48%)
not responding (but still able to release purines with the
stronger stimulus, 25 mM KCl+1 mM glutamate).
No ATP release can be detected
By replacing the null sensor with an ATP biosensor, we
investigated whether the purines detected arose from the
breakdown of extracellular ATP. The strong stimulus could
possibly result in cell death leading to ATP liberation from
the cytoplasm. In all experiments, no ATP could be
detected following stimulation (n=15 coverslips, detection
limit ∼60 nM, Fig. 1c). Electroporation of cells (with a 15–
25 V stimulus) released ATP (0.9±0.2 μM) but only a very
small amount of the released ATP was converted to
adenosine (∼4%, n=3, Fig. 1d). Addition of ATP
(100 μM) to the cultures resulted in the slow formation of
a small amount of adenosine (less than 2%, n=6, Fig. 1e).
Thus, although ectoATPases are present within the cultures,
they do not appear to be efficient enough or in sufficient
concentration to prevent ATP detection. Thus, we have no
evidence that the released purines arise from the breakdown
of extracellular ATP.
The purine released is not adenosine
We have used ADO biosensors (which detect adenosine,
inosine and hypoxanthine) and INO biosensors (which
Fig. 1 Purine release from granule cell cultures. a Traces from an
ADO and null sensor placed on the surface of a 2-week granule cell
culture (sensors were bent so that the sensing area was parallel to the
culture surface). Increasing the concentration of K
+ from 3 to 25 mM
with simultaneous application of 1 mM glutamate produced a large
current on the ADO biosensor but no response on the null sensor.
Inset, trace from a superimposed with a calibration trace (10 μM
adenosine, dotted line) illustrating the speed of the current rise due to
purine release is not defined by biosensor kinetics. b Trace from the
same culture as a but the ADO biosensor has been lifted from the
culture surface. Application of 25 mM KCl and 1 mM glutamate had
no effect on the ADO biosensor baseline. c Superimposed traces from
an adenosine biosensor (ADO) and an ATP biosensor placed on the
surface of a 2-week culture. Although a large concentration of
adenosine was released (following increase in K
+ concentration from
3 to 25 mM plus 1 mM glutamate) no ATP could be detected. d
Superimposed traces from an adenosine biosensor (ADO) and an ATP
biosensor placed on the surface of a 2-week culture. Application of a
high voltage stimulus (15 V) from a stimulating electrode placed
equidistant between the ADO and ATP biosensors produced the
release of ATP (by electroporation). However, there was very little
breakdown of the released ATP to adenosine. e Superimposed traces
from an adenosine biosensor (ADO) and an ATP biosensor placed on
the surface of a 2 week culture. Application of exogenous ATP
(100 μM) produced a rapid rise on the ATP biosensor and a much
smaller, slower rise on the ADO biosensor. Thus, the conversion of
ATP to adenosine is relatively slow and is not complete
b
342 Purinergic Signalling (2010) 6:339–348detect only inosine and hypoxanthine) to determine which
purines are released. Following a stimulus (25 mM KCl +
1 mM glutamate) the time to peak of currents on ADO and
INO biosensors was very similar and so were the current
amplitudes (once corrected for sensitivity, n=5, Fig. 2a).
This suggests that the analyte detected is not adenosine but
is either inosine or hypoxanthine as they can be detected by
both biosensors. This contrasts with purine release in
response to hypoxia in the hippocampus, where the signal
on the ADO biosensor has a much faster time to peak than
the signal on the INO signal demonstrating the release of
adenosine [17]. Application of adenosine (10 μM) to
cultures produced only a small, slow rising current on the
INO sensor (equivalent to 0.35±0.2 μM inosine, i.e. only
3.5% of adenosine is broken down to inosine, n=5,
Fig. 2b). Thus, it is unlikely that the inosine/hypoxanthine
detected by the biosensors arises from the rapid extracel-
lular breakdown of released adenosine. To confirm this, we
have used EHNA. EHNA blocks the conversion of
adenosine to inosine (by inhibiting adenosine deaminase),
thus prevents the detection of adenosine and inhibits
conversion of adenosine to inosine by adenosine deaminase
within the cultures [12]. EHNA (20 μM) had no significant
effect on the currents measured by ADO biosensors
(Fig. 2c, n=5). As a control, we checked that EHNA
blocks the detection of adenosine by ADO biosensors [12]
(Fig. 2d, n=3). Thus, the purine released is not adenosine
but instead is either inosine or hypoxanthine.
The release of inosine/hypoxanthine is via equilibrative
transport
We have investigated the mechanism of purines release.
Unlike electrical stimulation in cerebellar slices [12], purine
release was not blocked by TTX (1 μM Fig. 3a, n=3) and
thus does not require the firing of action potentials. In six
experiments, removal of extracellular Ca
2+ (substitution
with equivalent concentration of Mg
2+) prevented purine
release (Fig. 3b). However, in some experiments (n=3),
release was still observed when Ca
2+ was removed. By
using an ATP biosensor we discovered that when purine
release occurred in Ca
2+ free aCSF, it was accompanied
by a rapid release of large amounts of ATP (∼3 μM
Fig. 3c, n=3). In those cultures where no current was
produced on the ADO biosensor there was also no ATP
detected (n=2 coverslips) and thus the adenosine detected
probably arises from ATP metabolism. The mechanism of
ATP release is unclear but could be via hemi-channels [10]
or could represent cell death and subsequent release of
cytoplasmic contents.
Fig. 2 The purines released are adenosine metabolites. a, Super-
imposed traces from an ADO biosensor (dotted line) and INO
biosensor placed on the surface of a 2-week culture. Addition of the
stimulus (25 mM KCl and 1 mM glutamate) caused an increase in
current on both biosensors. The traces have been corrected for
sensitivity to inosine and have similar rise-times and amplitudes. b
Superimposed traces from an ADO and INO biosensor placed on the
surface of a 2-week culture. Application of 10 μMa d e n o s i n e
produced a large current on the ADO biosensor and a much smaller
and slower rising current on the INO biosensor. The arrow illustrates
that the ADO current is large when a current on the INO trace is first
observed. c Superimposed traces from an ADO biosensor in control
(solid line) and in 20 μM EHNA (dotted line). The same ADO
biosensor was placed on two different cultures. The stimulus (25 mM
KCl and 1 mM glutamate) was applied in control conditions on one
culture and after incubation (10–15 min) with 20 μM EHNA on the
other culture. EHNA had little effect on the ADO biosensor current
and thus the current must arise from the direct release of adenosine
metabolites (inosine and or hypoxanthine). d Trace from an ADO
biosensor. The current produced by adenosine (10 μM) was blocked
by co-application of EHNA (20 μM) and recovered in wash. The
dotted line is the baseline before adenosine application
b
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that inosine can be released by equilibrative transport [18].
To test if this mechanism occurs with granule cells cultures,
we have investigated the effects of the ENT blockers NBTI
(5 μM) and dipyridamole (10 μM) [19]. Following the
application of these transport blockers (for 10–15 min) the
release of purines was either greatly reduced or in some
cultures abolished (0.94±0.2 vs. 0.17±0.05 μM′ Fig. 3d,e
n=6). Following wash, release often recovered (Fig. 3d)
although the amount of recovery was variable. NBTI and
dipyridamole did not produce any current on the ADO
biosensor themselves and thus there appears to be very little
basal uptake of purines within the cultures.
A reliable method of inducing adenosine release in
cerebellar slices is to inhibit adenosine kinase (with
iodotubercidin) this results in the efflux of adenosine via
equilibrative transporters [20]. However, application of
iodotubercidin (2–4 μM) had no effect on the baseline
current of ADO biosensors (n=4, data not shown) and thus
basal adenosine kinase activity in the cultures must be low
(as a control, release could be evoked by KCl and
glutamate, following iodotubercidin application). Purines
can also be released from cerebellar slices by hypoxia [21].
However, prolonged hypoxia (10–15 min, bubbling with
N2/C02) had no effect on the ADO biosensor baseline (data
not shown) and thus does not induce purine release in
cultures (n=4 coverslips). Thus, the major mechanism of
purine release from the cultures is via equilibrative transport.
Purine release depends on culture composition
During the preparation of cultures we took steps to remove
glial cells (see “Methods” section and [16]) and thus
assumed that the purine release occurs from granule cells.
To confirm this and to investigate cell viability, we used
immunohistochemistry. GFAP antibodies were used to
identify glial cells and MAP-2 (neuronal dendritic protein)
antibodies to identify granule cells. In cultures 2–3 weeks
old, cultures were mixed, with granule cells growing on a
layer of glial cells (n=6 coverslips, Fig. 4a). During the
Fig. 3 The mechanism of purine release. a Trace from an ADO
biosensor placed on the surface of a 2–3-week-old culture. Pre-
incubation in 1 μM TTX does not prevent purine release following
application of 25 mM KCl and 1 mM glutamate. b Trace from an
ADO biosensor placed on the surface of a 2–3-week culture.
Application of Ca
2+-free aCSF (Mg
2+ increased to compensate for
Ca
2+ removal) caused a fall in the baseline current. Addition of
25 mM KCl and 1 mM glutamate did not cause the release of purines
but instead caused another fall in baseline. However, washing the Ca
2+
back in (whilst stimulus was still present) resulted in purine release. c
Traces from ATP and ADO biosensors placed on the surface of a 2–3-
week culture in zero Ca
2+ aCSF. Application of 25 mM KCl and
1 mM glutamate caused the release of ATP and adenosine, inosine, or
hypoxanthine. d Trace from an INO biosensor placed on the surface
of a 2–3-week culture. Pre-incubation with NBTI (5 μM) and
dipyridamole (10 μM) prevented purine release following application
of 25 mM KCl and 1 mM glutamate. Following wash off, NBTI/
dipyridamole (15–20 min) purine release occurred following the
stimulus. e Graph plotting mean concentration of purine released in
control and in NBTI/dipyridamole illustrating that NBTI/dipyridamole
significantly reduced purine release. Graph summarises data from six
experiments
b
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isolation must proliferate. Thus, the purine release mea-
sured could occur from either neurones or glia. There was
no difference in the morphology or number of granule cells
in stimulated (25 mM KCl and 1 mM glutamate) or
unstimulated cultures, suggesting the stimulus does not
produce wide spread cell death. To test the importance of
glia in the release of purines we took two approaches:
firstly, we assumed that 3–4-day-old cultures would contain
very few glial cells, as there is little time for proliferation.
This was confirmed by immunohistochemistry (Fig. 4b,
n=5). We were unable to record any purine release from
these cultures (25 mM KCl and 1 mM glutamate, n=10
coverslips). In 7-day-old cultures, purine release occurred
in ∼50% of cultures (n=6 out of ten coverslips). In such
cultures, the number of glia had increased (not illustrated).
By 2 weeks, purine release was very reliable (see earlier).
Although the reliability of purine release matches glial cell
proliferation, it is also possible that neuronal differentia-
tion occurs over this period and changes in the expression
of proteins (such as ENTs) could account for the differences
in purine release. Secondly, we grew cultures in the presence
of the mitotic inhibitor (1 μM β-D-arabinofuranoside
hydrochloride) which reduces glial cell proliferation. Immu-
nostaining of 2–3-week-old cultures revealed a clear
reduction in the number of glia in cultures treated with the
mitotic inhibitor (Fig. 4c). There was also a significant (P<
0.01) reduction in the amount of purines released from cells
cultured in the presence of the mitotic inhibitor (1.18±
0.14 μM′ vs 2.96±0.6 μM′, six coverslips with a mitotic
inhibiter and six control coverslips, interleaved experi-
ments). This reduction in purine release could specifically
reflect the loss of glia or could simply result from a
reduction in total cell number if both neurones and glia
release purines. In glia-only cultures (confirmed by immuno-
histochemistry,Fig.4d), we could detect no purine release in
response to KCl (25 mM) and glutamate (1 mM, n=10) but
release was sometimes observed in response to the removal
of extracellular Ca
2+ (not illustrated). Interpretation of this
data is difficult as changes in culture composition may affect
21 day 
culture
Map-2 GFAP
4 day
culture
Mitotic
inhibitor
astrocyte
cultures
a
b
c
d
null
25 s
100 pA
ADO
Fig. 4 Culture composition
determines purine release.
Culture composition was deter-
mined by marking neuronal
dendrites with MAP-2 anti-
bodies (green) and marking glia
with GFAP antibodies (red).
Purine release was evoked by
addition of 25 mM KCl and
1 mM glutamate (black bar) and
monitored with an ADO bio-
sensor and null sensor placed on
the culture surface. Example
photographs and biosensor
traces from: a 21-day culture,
b 4-day culture, c 21-day culture
with mitotic inhibitor present,
d astrocyte only culture. Pictures
were taken using an SP2
confocal microscope (single
scan). Scale bar for photographs
(a, b and c)i s3 0μm and
50 μm( d). Note the different
morphology of glia when
cultured alone compared to
morphology when cultured
with neurones
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that cultures are mixed (neurones and glia) and there is no
obvious change in cell morphology (and presumably cell
viability) following stimulation.
Purines release in acute cerebellar slices differs from release
in cultures
To investigate whether a similar mechanism of purine
release occurs in cerebellar slices, we have applied the same
stimulus (25 mM K
+ and 1 mM glutamate) to cerebellar
slices and measured purine release with biosensors.
Although it is not possible to directly compare the age of
animals used for slices with the days in culture, we have
used slices from two ages of rats (P7–9 and P21–25) to
investigate possible changes in purine release during
cerebellar development.
In cerebellar slices from P7–9 rats addition of KCl
(25 mM) and glutamate (1 mM) produced a large current on
the ADO biosensor (449±66 pA, Fig. 5a), with no current
on the null sensor (n=6). This current was equivalent to the
release of 2.5±0.2 μM′ adenosine/inosine. We found that
the properties of release were similar to those found for
release in cultures (Fig. 5b): not blocked by TTX (1 μM,
n=3), Ca
2+ dependent (n=4) and not accompanied by ATP
release (n=6). Blocking conversion of adenosine to inosine
with EHNA (20 μM, n=3) had only a small effect on the
current (∼25% reduction) suggesting that the majority of
the purine released was not adenosine. However, unlike
cultures, purine release from cerebellar slices was not
reduced by prolonged incubation (20–30 min) with NBTI
(5 μM) and dipyridamole (10 μM, n=4). Thus, the purine
release in slices did not appear to occur via a transporter
which is sensitive to NBTI/dipyridamole.
In cerebellar slices from P21–25 rats addition of KCl
(25 mM) and glutamate (1 mM) also produced a large
current on the ADO biosensor (299±65 pA, equivalent to
1.46±0.5 μM′ adenosine/inosine, n=6). Purine release was
similar to release in slices from younger rats (Fig. 5b)i n
that it was insensitive to TTX (1 μM, n=3), relatively
insensitive to EHNA (20 μM, ∼15% reduction, n=3) and
insensitive to NBTI (5 μM) /dipyridamole (10 μM, n=4).
However, unlike purine release in slices from younger rats
and in cultures, purine release was not inhibited by the
removal of extracellular Ca
2+ with no ATP detected on ATP
biosensors (n=4).
Discussion
We have used granule cell cultures to investigate whether the
adenosine release observed in cerebellar slices [12] could be
from granule cell axons. Although it was not possible to
detect the action-potential dependent release of adenosine
from granule cell cultures, it was possible to detect the
release of adenosine metabolites (inosine/hypoxanthine) in
response to a depolarising (stressful) stimulus. Although
similar data has been described in other brain areas [7], this
is the first time that purine release has been measured from
primary cultured cells in real-time using microelectrode
biosensors.
There are several possible reasons why the release of
adenosine observed in slices was not observed in granule
cell cultures. The simplest is that the adenosine release
observed in slices is not from granule cells but instead is
from a downstream target of parallel fibres and this target is
Fig. 5 The same stimulus produces purine release in acute cerebellar
slices but release is not blocked by ENT inhibition. a Traces from
ADO and ATP biosensors placed on the surface of the molecular layer
of a cerebellar slice from a P8 rat. Addition of 25 mM KCl and 1 mM
glutamate produced a large current on the ADO biosensor but no
signal on the ATP biosensor. b Graph summarising the effects of
manipulations (addition of 1 μM TTX, removal of extracellular Ca
2+,
addition of 20 μM EHNA, addition of 5 μM NBTI and 10 μM
dipyridamole) on purine release from slices from P7–9 rats and from
P21–23 rats (n=3–6 for each manipulation). The normalised purine
release was calculated by dividing each manipulated (i.e. with zero
Ca
2+ or with a drug present) purine release current by the average
current in control conditions. Data was corrected for differences in
biosensor sensitivity across experiments
346 Purinergic Signalling (2010) 6:339–348absent from cultures. Such a target could be large cells such
as Bergmann glia and Purkinje cells which are not present
in the cultures. Alternatively, the cells in cultures are
isolated from the cerebella of rats which are 7–8 days old.
As it is not possible to record activity-dependent adenosine
release in cerebellar slices from P7–10 rats [20], the
mechanism of adenosine release may not be present in
cultured cells if they do not develop further whilst in
culture. Lastly, it could be that the cells (granule cells and
glia) present in culture have different properties than those
in acute cerebellar slices. The cells are cultured in
25 mM K
+ which greatly increases cell survival but may
well change their properties, e.g. a greater resting [Ca
2+]i
may induce widespread gene expression. This possibility is
supported by the observation that NBTI/dipyridamole-
sensitive purine release that occurs in cultures is not
observed in slices. Thus, either a different mechanism
releases purines in cultured cells or a different transporter is
involved. We have previously observed [20, 21] that in
many slices, the efflux of adenosine produced by blocking
adenosine kinase (with iodotubercidin) is not inhibited by
blocking ENTs with NBTI/dipyridamole. Thus, the cells in
slices either have a transporter which is insensitive to
NBTI/dipyridamole or release purines by a transporter-
independent mechanism. This difference between cultures
and slices high lights the problem of extrapolating the
mechanisms of purine release between different models.
Mechanisms of purine release in culture
Using a strongly depolarising and stressful stimulus (25 mM
KCl and 1 mM glutamate), it was possible to reliably release
inosine/hypoxanthine from granule cell cultures. Our data
suggests that this stimulus results in the intracellular build-
up of either inosine or hypoxanthine inside cells which is
then transported from the cell via an NBTI/dipyridamole-
sensitive equilibrative transporter (ENT). It is unlikely that
the intracellular inosine/hypoxanthine arise from the
breakdown of adenosine, as blocking adenosine deaminase
with EHNA had no effect on release [22]. Thus presum-
ably intracellular AMP is converted to IMP plus ammonia
(by AMP deaminase) and then IMP is metabolised to
inosine (by 5′nucleotidases) [23]. The ammonia produced is
potentially toxic; for example, there is evidence that it
produces swelling of astrocytes following liver failure [24].
The conversion of AMP to IMP predominates in rat C6
glioma cells in ATP depleting conditions [25]. The involve-
ment of AMP deaminase is supported by the observation
that the release of inosine/hypoxanthine is Ca
2+ dependent.
The affinity of AMP deaminase for AMP is increased in the
presence of Ca
2+ in human red blood cells [26] and Ca
2+-
calmodulin activates erythrocyte AMP deaminase [27]. The
AMP appears to be produced as a result of intracellular
ATP metabolism rather than the conversion of adenosine to
AMP asblockingadenosine kinasedid not resultinadenosine
release. Studies in cortical neuron/astrocyte cultures [18, 22]
have shown that inosine is released in an ENT-dependent
mechanism from neurones in response to metabolic stress
(oxygen/glucose deprivation or sodium cyanide). The
stimulus we have used (KCl and glutamate) will produce
an increase in ATP metabolism because of the activation of
exchange pumps following prolonged depolarisation and
resultant ion movements. The influx of Ca
2+ into cells is
required for release (maybe to activate AMP deaminase) and
this presumably comes via the opening of HVA Ca
2+
channels and possibly via glutamate receptor channels.
Why is inosine/hypoxanthine released rather than adeno-
sine? It is possible that the breakdown products of ATP
metabolism are expelled from cells and have no signalling
role. This seems unlikely as it would result in the loss of
purines from the cells. Inosine is suggested to have a
signalling role, activating A3 receptors [28]. There is also
evidence that inosine/hypoxanthine may play a neurotrophic
role [29]. For example, inosine can stimulate morphological
and biochemical differentiation in primary cultures of chick
sympathetic neurons [30]. Inosine can also enhance the
effects of NGF on neurite extension in PC12 cells [31].
The synthetic hypoxanthine derivative AIT-082 enhances the
outgrowth of neurites in primary neuronal cultures [32].
Administration of hypoxanthine significantly improved
somatosensory evoked potential recovery following ischemic
brain injury [33] .T h ep u r i n em e t a b o l i t eu r a t ei sap r e d i c t o r
of decline during Parkinson’s disease, possibly suggesting
raised levels of neuroprotective purines [34].
Which cells in culture release purines? This is currently
unclear. Reducing the number of glia in cultures reduces
purine release and neurone only cultures do not release
purines. However, purine release does not occur in glia-
only cultures. These results have to be interpreted with
caution as the astrocytes cultured without neurones clearly
had a different morphology from those cultured with
neurones and there was also a difference in neurones grown
with reduced glia, neuronal processes were much more
blebbed and cell bodies were stained more widely (not
illustrated). Thus, the change in growing conditions may
well affect the purine release mechanism and thus it is not
possible to currently conclude which cells actually release
purines in response to stimulation. However, it appears that
the interaction between neurones and glia results in one or
other (or both) cell types becoming competent to release
purines.
The mechanisms of purine release remain controversial
and as yet are not fully resolved. This study shows that
purine release is highly complex and great care must be
used when extrapolating between different stimuli and
model systems.
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